Sai Life Sciences, one of India’s fastest-growing contract research, development and manufacturing organisations (CRDMOs), has announced a major hiring initiative aimed at expanding its Process Research & Development (PR&D) and Analytical Research & Development (AR&D) teams as it scales its scientific capabilities to meet growing global demand. The recruitment drive forms part of the company’s FY27 expansion strategy and is aligned with the continued growth of its Chemistry, Manufacturing and Controls (CMC) business. Sai Life Sciences plans to induct scientific team leaders, group leaders and research professionals across a range of advanced therapeutic modalities and technology platforms.
The company is looking to strengthen expertise in areas such as peptides, antibody-drug conjugates (ADCs), oligonucleotides, flow chemistry and analytical sciences, reflecting the pharmaceutical industry’s increasing focus on next-generation therapies and complex drug development programmes.
Krishna Kanumuri, Managing Director and Chief Executive Officer, Sai Life Sciences, said the company is making sustained investments in scientific capability to support innovation-led pharmaceutical and biotechnology companies worldwide. “As therapeutic science continues to evolve, the need for deep scientific expertise has never been greater. Alongside investments in infrastructure and technology, we are focused on attracting exceptional scientific talent capable of solving complex development challenges. Our objective is to build research capabilities that match the highest global standards while creating an environment where scientists can grow, innovate and make a meaningful impact,” he said.
Sai Life Sciences is inviting applications from experienced PhD-qualified scientists, chemical engineers and professionals with expertise in pharmaceutical research and development. The company is also opening opportunities for promising early-career researchers, including PhD graduates and post-doctoral fellows who demonstrate strong scientific potential.
Candidates joining the organisation will work on research programmes spanning small molecules and advanced therapeutic modalities for leading global pharmaceutical and biotechnology companies. They will also gain access to cross-functional projects, specialised training and mentorship from experienced scientific leaders across multiple disciplines.
The expansion is expected to further strengthen Sai Life Sciences’ position in the rapidly evolving CRDMO sector, where demand for integrated research, development and manufacturing services continues to grow. Over the past few years, the company has invested significantly in expanding its research infrastructure, technology platforms and scientific workforce to support global drug discovery and development programmes.
Headquartered in India with operations across the United Kingdom and the United States, Sai Life Sciences provides end-to-end contract research, development and manufacturing services to innovator pharmaceutical and biotechnology companies. Its capabilities span the entire drug development value chain, supporting customers from early-stage discovery through commercial manufacturing.
